Axonics, Inc. (AXNX) Tops Q3 EPS by 13c, Offers FY22 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Axonics, Inc. (AXNX) Tops Q3 EPS by 13c, Offers FY22 Revenue Guidance

Axonics® Reports Third Quarter 2022 Financial Results

October 31, 2022 4:01 PM EDT

Generated record quarterly revenue of $70 million, an increase of 50% year over year

Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022.

This quarters record revenue result reflects growing demand from physicians and their patients for our best-in-class incontinence... More